Edesa Biotech, Inc. (EDSA) Financials

EDSA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$7.2M -16.5% YoY

EPS (Diluted) Not reported for FY2025

Operating Cash Flow -$7.3M -49.7% YoY

Market Cap $40.8M as of Sep 12, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 4.6x on $8.8M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE September

Newest figures come from the 10-Q for Q3 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EDSA SEC filings page.

This page shows Edesa Biotech, Inc. (EDSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EDSA FY2025 2026-08-29

External financing is carrying a cash-consuming operation while the FY2025 balance sheet looks far stronger than earnings.

Operating cash flow essentially matched net loss in FY2023 and stayed close in FY2025, indicating reported losses were translating into cash outflows rather than being mainly non-cash accounting charges. That cash need was paired with $17.0M of financing inflow in FY2025, helping explain the simultaneous rebound in assets and short-term liquidity despite another annual loss.

FY2025 current ratio of 10.7x and debt-to-equity of 0.1x describe a balance sheet that is currently liquid and lightly debt-funded; the constraint is operating cash generation, not near-term leverage.

R&D and SG&A were $3.7M and $4.2M in FY2025, showing spending was split nearly evenly between development and corporate or selling overhead. Operating losses narrowed through FY2024 before widening in FY2025, indicating earlier cost improvement had not become a consistent trajectory.

Financial Health Signals

Financial health score not available

Edesa Biotech, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Edesa Biotech, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Edesa Biotech, Inc. reported a net loss of $7.2M while operations used $7.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$5.5M

YoY-192.5%

QoQ-28.6%

Edesa Biotech, Inc.'s EBITDA was -$5.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 192.5% from the same quarter a year earlier. Against the prior quarter it is down 28.6%.

Net Income

-$5.4M

YoY-209.1%

QoQ-28.2%

Edesa Biotech, Inc. reported -$5.4M in net income in Q3 2026. This represents a decrease of 209.1% from the same quarter a year earlier. Against the prior quarter it is down 28.2%.

Revenue

Not reported for Q3 2026.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$10.3M

YoY-16.9%

QoQ+3.0%

5Y CAGR+5.0%

10Y CAGR+8.0%

Edesa Biotech, Inc. held $10.3M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

10M

YoY+37.0%

QoQ+8.4%

5Y CAGR-6.2%

10Y CAGR-0.5%

Edesa Biotech, Inc. had 10M shares outstanding in Q3 2026. This represents an increase of 37.0% from the same quarter a year earlier. Against the prior quarter it is up 8.4%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-61.4%

YoY-49.0pp

QoQ-20.0pp

Edesa Biotech, Inc.'s ROE was -61.4% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 49.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.0 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$4.0M

YoY+321.5%

QoQ+43.0%

Edesa Biotech, Inc. invested $4.0M in research and development in Q3 2026. This represents an increase of 321.5% from the same quarter a year earlier. Against the prior quarter it is up 43.0%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

EDSA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EDSA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$329K	$0-100.0%	$228K-82.0%	$1.3M+67.6%	$759K+103.9%	$372K-31.8%	$545K+90.7%	$286K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$18K	$133K-46.7%	$250K-69.5%	$819K+40.9%	$581K+23.8%	$469K+718.0%	$57K-86.5%	$426K
Gross Profit	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$311K	-$133K-512.8%	-$22K-104.8%	$453K+154.8%	$178K+283.3%	-$97K-119.9%	$488K+448.0%	-$140K
R&D Expenses	N/A	$3.7M+27.3%	$2.9M-39.9%	$4.8M-64.0%	$13.3M-25.7%	$17.9M+439.0%	$3.3M	$1.1M-45.5%	$2.0M+14.1%	$1.7M+68.0%	$1.0M-58.1%	$2.5M+21.8%	$2.0M-23.4%	$2.6M
SG&A Expenses	N/A	$4.2M+2.7%	$4.1M-6.7%	$4.4M-12.1%	$5.0M-12.2%	$5.7M+69.5%	$3.4M	$543K-81.6%	$2.9M-11.4%	$3.3M+3.0%	$3.2M+12.4%	$2.9M+62.2%	$1.8M-51.6%	$3.7M
Operating Income	N/A	-$7.9M-12.8%	-$7.0M+23.9%	-$9.2M+49.8%	-$18.4M+22.4%	-$23.7M-270.0%	-$6.4M	-$1.6M+69.0%	-$5.2M-6.4%	-$4.9M-13.1%	-$4.3M+24.1%	-$5.7M	N/A	N/A
EBITDA	N/A	-$7.8M-14.1%	-$6.8M+24.5%	-$9.0M+50.5%	-$18.3M+22.5%	-$23.6M-271.5%	-$6.3M	-$1.6M+68.0%	-$5.0M-6.0%	-$4.8M-13.9%	-$4.2M+24.8%	-$5.6M	N/A	N/A
Income Tax	N/A	$8000.0%	$8000.0%	$8000.0%	$8000.0%	$8000.0%	$800	$0-100.0%	$800-88.9%	$7K-80.4%	$37K+35.3%	$27K+3300.0%	$8000.0%	$800
Net Income	N/A	-$7.2M-16.5%	-$6.2M+26.3%	-$8.4M+52.3%	-$17.5M-31.5%	-$13.3M-109.7%	-$6.4M	-$1.5M+69.5%	-$5.0M-0.1%	-$5.0M-76.8%	-$2.8M+66.3%	-$8.4M+41.8%	-$14.5M-162.2%	-$5.5M
EPS (Basic)	N/A	-$1.27+34.2%	-$1.93+34.1%	-$2.93	N/A	N/A	N/A	N/A	N/A	-$0.57-58.3%	-$0.36+67.6%	-$1.11+60.5%	-$2.81	N/A
EPS (Diluted)	—	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.57-58.3%	-$0.36	-$1.11+60.5%	-$2.81	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9M+10.9%	8M	8M+46.9%	5M	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
R&D Expenses	$4.0M+321.5%	$2.8M+471.4%	$1.1M+10.3%	N/A	$939K+4.7%	$484K-58.8%	$1.0M+44.8%	N/A
SG&A Expenses	$1.6M+61.9%	$1.5M+32.5%	$1.2M+38.4%	N/A	$965K-6.8%	$1.2M+10.6%	$879K-23.8%	N/A
Operating Income	-$5.5M-189.9%	-$4.3M-162.2%	-$2.3M-23.3%	N/A	-$1.9M+1.5%	-$1.6M+26.2%	-$1.9M-2.2%	N/A
EBITDA	-$5.5M-192.5%	-$4.3M-164.6%	-$2.3M-24.8%	N/A	-$1.9M+0.2%	-$1.6M+25.8%	-$1.9M-2.4%	N/A
Income Tax	$0	$8000.0%	N/A	N/A	$0	$8000.0%	N/A	N/A
Net Income	-$5.4M-209.1%	-$4.2M-165.2%	-$2.2M-39.0%	N/A	-$1.7M-4.9%	-$1.6M+14.6%	-$1.6M+3.6%	N/A
EPS (Basic)	-$0.60-140.0%	-$0.49-63.3%	-$0.28+41.7%	-$0.32-10.3%	-$0.25+51.9%	-$0.30+48.3%	-$0.48+11.1%	-$0.29+48.2%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, EPS (Diluted), Diluted Shares (Avg).

EDSA Balance Sheet

EDSA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$13.5M+254.8%	$3.8M-57.1%	$8.9M-23.2%	$11.6M-20.6%	$14.6M+35.5%	$10.8M	$3.4M-56.0%	$7.7M-40.3%	$12.9M+24.6%	$10.4M-30.0%	$14.8M-7.7%	$16.1M	N/A
Current Assets	$11.5M+587.1%	$1.7M-74.0%	$6.4M-29.2%	$9.1M-24.8%	$12.1M+49.2%	$8.1M	$3.4M-49.8%	$6.8M-44.1%	$12.1M+22.6%	$9.9M-31.6%	$14.4M+77.3%	$8.1M	N/A
Cash & Equivalents	$10.8M+980.0%	$1.0M-81.5%	$5.4M-23.8%	$7.1M-9.5%	$7.8M+8.7%	$7.2M	$3.4M-26.3%	$4.6M-38.4%	$7.4M+87.5%	$4.0M-54.9%	$8.8M-43.3%	$15.5M+1449.4%	$999K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$1.6M-19.8%	$2.0M-50.0%	$4.0M-20.5%	$5.0M-8.0%	$5.5M	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$68K-72.7%	$249K-55.2%	$557K+1497.2%	$35K	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$56K+215.7%	$18K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.1M-41.2%	$1.8M-0.5%	$1.8M-15.7%	$2.2M+43.1%	$1.5M-63.1%	$4.1M	$184K-42.7%	$321K-48.5%	$624K-73.8%	$2.4M-45.4%	$4.4M-59.3%	$10.7M	N/A
Current Liabilities	$1.1M-41.2%	$1.8M+0.6%	$1.8M-14.9%	$2.1M+46.8%	$1.5M-4.7%	$1.5M	$184K-42.7%	$321K-48.5%	$624K-73.8%	$2.4M+254.2%	$672K-82.6%	$3.9M	N/A
Non-Current Liabilities	$0	$0-100.0%	$20K-54.7%	$44K-35.5%	$68K-97.4%	$2.6M	$0	$0	$0	$0-100.0%	$3.7M-46.0%	$6.8M	N/A
Total Equity	$12.5M+528.5%	$2.0M-71.9%	$7.0M-24.9%	$9.4M-28.1%	$13.1M+96.9%	$6.6M	$3.2M-56.6%	$7.4M-39.9%	$12.3M+53.8%	$8.0M-23.5%	$10.5M+60.1%	$6.5M+624.6%	$902K
Retained Earnings	-$65.9M-12.5%	-$58.6M-11.8%	-$52.4M-19.0%	-$44.0M-66.2%	-$26.5M-101.7%	-$13.1M	-$3.8M+91.7%	-$45.4M-12.5%	-$40.4M-14.2%	-$35.3M-8.7%	-$32.5M-29.0%	-$25.2M	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$12.7M-14.1%	$12.4M-24.7%	$14.7M+253.3%	$13.5M+254.8%	$14.8M+183.2%	$16.5M+154.1%	$4.2M-46.8%	$3.8M-57.1%
Current Assets	$10.8M-15.5%	$10.4M-27.6%	$12.7M+513.8%	$11.5M+587.1%	$12.8M+318.9%	$14.4M+239.1%	$2.1M-61.7%	$1.7M-74.0%
Cash & Equivalents	$10.3M-16.9%	$10.0M-28.1%	$12.1M+656.3%	$10.8M+980.0%	$12.4M+507.6%	$13.9M+396.5%	$1.6M-62.5%	$1.0M-81.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.9M+481.3%	$2.2M+139.2%	$756K-60.2%	$1.1M-41.2%	$673K-71.5%	$915K-57.5%	$1.9M-4.4%	$1.8M-0.5%
Current Liabilities	$3.9M+481.3%	$2.2M+139.2%	$756K-60.2%	$1.1M-41.2%	$673K-71.5%	$915K-57.5%	$1.9M-4.4%	$1.8M+0.6%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Total Equity	$8.8M-37.7%	$10.2M-34.4%	$14.0M+516.4%	$12.5M+528.5%	$14.1M+392.9%	$15.5M+259.4%	$2.3M-61.3%	$2.0M-71.9%
Retained Earnings	-$77.9M-22.4%	-$72.5M-17.1%	-$68.2M-13.2%	-$65.9M-12.5%	-$63.6M-10.4%	-$61.9M-10.5%	-$60.2M-11.3%	-$58.6M-11.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

EDSA Cash Flow Statement

EDSA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$8.9M	-$7.3M-49.7%	-$4.9M+26.3%	-$6.6M+46.0%	-$12.3M+10.1%	-$13.7M-174.0%	-$5.0M	-$1.3M+72.6%	-$4.7M-4.3%	-$4.5M-2.1%	-$4.4M-3.4%	-$4.3M-52.6%	-$2.8M+29.2%	-$3.9M
Depreciation & Amortization	N/A	$119K-35.9%	$186K+1.4%	$183K+55.2%	$118K-0.5%	$119K+106.4%	$58K	$2K-99.1%	$179K+19.9%	$150K-6.2%	$160K+0.8%	$158K+26.8%	$125K+11.3%	$112K
Stock-Based Compensation	N/A	$730K+35.7%	$537K-56.9%	$1.2M-44.9%	$2.3M-29.3%	$3.2M+434.0%	$598K	$81K-29.6%	$116K-55.5%	$259K-2.9%	$267K-72.1%	$957K+21.6%	$787K-59.1%	$1.9M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$6K-8.0%	$6K+26.6%	$5K	$7K-97.7%	$303K-24.7%	$402K+46.5%	$275K-1.6%	$279K+2824.9%	$10K-87.8%	$78K
Free Cash Flow	N/A	N/A	N/A	-$6.6M+46.0%	-$12.3M+10.1%	-$13.7M-173.9%	-$5.0M	-$1.3M+74.1%	-$5.0M-1.9%	-$4.9M-4.7%	-$4.7M-3.1%	-$4.5M-62.0%	-$2.8M+30.3%	-$4.0M
Investing Cash Flow	N/A	N/A	N/A	$0+100.0%	-$6K+8.0%	-$6K-132.2%	$19K	-$7K-100.4%	$1.7M+203.5%	$557K+355.1%	$122K	N/A	N/A	N/A
Financing Cash Flow	$7.0M	$17.0M+2776.7%	$592K-87.7%	$4.8M-58.5%	$11.6M-18.0%	$14.2M+99.8%	$7.1M	$8.8M	$0-100.0%	$7.3M+6748.8%	$107K	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$3.1M-81.3%	-$2.0M+15.4%	-$2.1M-37.6%	-$1.7M-78.0%	-$1.7M-98.6%	-$2.4M-43.6%	-$1.5M-7.9%	-$967K+34.1%
Depreciation & Amortization	$26K-0.6%	$26K+5.6%	$25K-40.9%	$26K-41.5%	$26K-49.8%	$25K-46.0%	$43K-4.3%	$44K-3.8%
Stock-Based Compensation	$500K+150.0%	$480K+585.7%	$400K+392.5%	N/A	$200K+100.0%	$70K-53.2%	$81K-56.0%	N/A
Financing Cash Flow	$3.4M	-$9K-100.1%	$3.4M+62.0%	$186K+693.2%	$0-100.0%	$14.8M+6878.2%	$2.1M+577.5%	-$31K-107.6%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

EDSA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EDSA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	94.7%	N/A	-9.5%-45.2pp	35.6%+12.2pp	23.4%+49.5pp	-26.1%-115.6pp	89.5%+138.5pp	-49.0%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-1946.7%	N/A	-2288.6%	-386.0%	-571.9%	-1536.7%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-1935.3%	N/A	-2203.7%	-395.2%	-374.7%	-2267.9%	-2657.5%	-1933.0%
Return on Equity	-57.7%+253.7pp	-311.4%-192.6pp	-118.8%+68.1pp	-186.9%-84.7pp	-102.2%-6.2pp	-96.0%	-47.8%+20.2pp	-68.0%-27.2pp	-40.8%-5.3pp	-35.5%+45.1pp	-80.7%+141.1pp	-221.8%+391.1pp	-612.9%
Return on Assets	-53.1%+108.7pp	-161.8%-67.6pp	-94.2%+57.4pp	-151.6%-60.1pp	-91.5%-32.4pp	-59.1%	-45.2%+19.9pp	-65.2%-26.3pp	-38.9%-11.5pp	-27.4%+29.6pp	-56.9%+33.3pp	-90.2%	N/A
Current Ratio	10.67+9.8x	0.91-2.6x	3.53-0.7x	4.25-4.0x	8.29+3.0x	5.30	18.45-2.6x	21.06+1.7x	19.40+15.3x	4.14-17.3x	21.46+19.4x	2.10	N/A
Debt-to-Equity	0.09-0.8x	0.93+0.7x	0.260.0x	0.23+0.1x	0.12-0.5x	0.62	0.060.0x	0.040.0x	0.05-0.2x	0.30-0.1x	0.42-1.2x	1.64	N/A
Asset Turnover	N/A	N/A	N/A	N/A	0.000.0x	0.03	0.000.0x	0.03-0.1x	0.100.0x	0.070.0x	0.030.0x	0.03	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	-1518.0%	N/A	-2191.3%	-385.9%	-617.8%	-1221.5%	-514.3%	-1407.5%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Return on Equity	-61.4%-49.0pp	-41.4%-31.1pp	-16.1%+55.3pp	N/A	-12.4%+45.8pp	-10.2%+32.8pp	-71.4%-42.7pp	N/A
Return on Assets	-42.5%-30.7pp	-34.1%-24.4pp	-15.3%+23.6pp	N/A	-11.8%+20.1pp	-9.7%+19.1pp	-38.8%-17.4pp	N/A
Current Ratio	2.76-16.2x	4.76-11.0x	16.82+15.7x	10.67+9.8x	18.97+17.7x	15.73+13.8x	1.09-1.6x	0.91-2.6x
Debt-to-Equity	0.44+0.4x	0.21+0.2x	0.05-0.8x	0.09-0.8x	0.05-0.8x	0.06-0.4x	0.84+0.5x	0.93+0.7x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Edesa Biotech, Inc. EDSA	FY2025	N/A	-$7.2M	N/A	$40.8M	—
NovaBay Pharmaceuticals, Inc. NBY	FY2025	N/A	N/A	N/A	$51.9M	—
BioLineRX Ltd BLRX	FY2025	$1.2M	-$2.0M	N/A	$12.5M	17/100
Tharimmune, Inc. THAR	FY2025	N/A	-$35.9M	N/A	$187.4M	—
MetaVia Inc. MTVA	FY2025	N/A	-$13.0M	N/A	$11.5M	—
Longeveron Inc. LGVN	FY2025	$1.2M	-$22.7M	N/A	$21.2M	44/100

Where Edesa Biotech, Inc. Ranks

Frequently Asked Questions

Is Edesa Biotech, Inc. profitable?

No, Edesa Biotech, Inc. (EDSA) reported a net income of -$7.2M in fiscal year 2025.

What is Edesa Biotech, Inc.'s EBITDA?

Edesa Biotech, Inc. (EDSA) had EBITDA of -$7.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Edesa Biotech, Inc.'s return on equity (ROE)?

Edesa Biotech, Inc. (EDSA) has a return on equity of -57.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Edesa Biotech, Inc.'s operating cash flow?

Edesa Biotech, Inc. (EDSA) recorded an outflow of $7.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Edesa Biotech, Inc.'s total assets?

Edesa Biotech, Inc. (EDSA) had $13.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Edesa Biotech, Inc. spend on research and development?

Edesa Biotech, Inc. (EDSA) invested $3.7M in research and development during fiscal year 2025.

How many shares does Edesa Biotech, Inc. have outstanding?

Edesa Biotech, Inc. (EDSA) had 8M shares outstanding as of fiscal year 2025.

What is Edesa Biotech, Inc.'s current ratio?

Edesa Biotech, Inc. (EDSA) had a current ratio of 10.67 as of fiscal year 2025, which is generally considered healthy.

What is Edesa Biotech, Inc.'s debt-to-equity ratio?

Edesa Biotech, Inc. (EDSA) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Edesa Biotech, Inc.'s return on assets (ROA)?

Edesa Biotech, Inc. (EDSA) had a return on assets of -53.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Edesa Biotech, Inc.'s P/E ratio?

Edesa Biotech, Inc. (EDSA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $40.8M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Edesa Biotech, Inc.'s price-to-sales ratio?

Edesa Biotech, Inc. (EDSA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $40.8M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Edesa Biotech, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Edesa Biotech, Inc. (EDSA) held $10.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.3M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Edesa Biotech, Inc.'s Piotroski F-Score?

Edesa Biotech, Inc. (EDSA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Edesa Biotech, Inc.'s earnings high quality?

Edesa Biotech, Inc. (EDSA) reported a net loss of $7.2M while operations used $7.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.